Urogenital diseases articles within Nature Reviews Clinical Oncology

Featured

• News & Views | 17 November 2023

  Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients

  Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients. This trial heralds a new era in demonstrating the feasibility of bladder preservation for selected patients with MIBC.

  • Jakob Klemm
  • , Ekaterina Laukhtina
  •  & Shahrokh F. Shariat

• Research Highlight | 04 January 2023

  Targeted biopsy reduces detection of clinically insignificant cancer

  • Diana Romero

• Research Highlight | 23 May 2022

  Combination improves salvage outcomes

  • Diana Romero

• Research Highlight | 28 March 2018

  DDR signature to predict response to ICI

  • Diana Romero

• Research Highlight | 07 April 2015

  New biomarker panel prognosticates patient survival

  • Peter Sidaway

• Research Highlight | 27 May 2014

  Accelerating MVAC

  • David Killock

• Review Article | 13 May 2014

  Circulating tumour cells—monitoring treatment response in prostate cancer

  Circulating tumour cells (CTCs) might be representative of the tumour burden and might also provide information on tumour cell biology. As such, these cells hold promise in the prediction and monitoring of response to anticancer therapy. In this Review, the authors highlight the challenges of monitoring treatment response in metastatic castrate-resistance prostate cancer and discuss the developments in CTC analyses that have increased the value of these cells as potential biomarkers in this disease.

  • David T. Miyamoto
  • , Lecia V. Sequist
  •  & Richard J. Lee

• Research Highlight | 24 September 2013

  Another option for metastatic RCC

  • Lisa Hutchinson

• Research Highlight | 03 September 2013

  Reduction in the risk of prostate cancer with finasteride

  • Vanessa Marchesi

• Research Highlight | 30 April 2013

  Second-line option for metastatic RCC

  • Vanessa Marchesi

• Research Highlight | 13 March 2012

  Endometriosis link to invasive subtypes

  • Iley Ozerlat